Esperion to Participate in Upcoming September Investor Conferences
Esperion (NASDAQ: ESPR), a commercial stage biopharmaceutical company, announced its participation in two upcoming investor conferences in September 2025: the Cantor Global Healthcare Conference on September 3 at 9:45 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 2:00 p.m. ET.
The company specializes in FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk, supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through partnerships and pipeline advancement.
Esperion (NASDAQ: ESPR), una società biofarmaceutica in fase commerciale, ha annunciato la sua partecipazione a due prossimi convegni per investitori a settembre 2025: il Cantor Global Healthcare Conference il 3 settembre alle 9:45 ET e il H.C. Wainwright 27th Annual Global Investment Conference l'8 settembre alle 14:00 ET.
L'azienda è specializzata in farmaci orali approvati dalla FDA, da assumere una volta al giorno e non appartenenti alla classe delle statine, destinati a pazienti con LDL-C elevato e rischio cardiovascolare, supportati dallo studio CLEAR sui risultati cardiovascolari che ha coinvolto 14.000 pazienti. Esperion sta inoltre sviluppando inibitori di nuova generazione della ATP citrate lyase (ACLYi) e si sta espandendo a livello globale tramite partnership e l'avanzamento del proprio pipeline.
Esperion (NASDAQ: ESPR), una compañía biofarmacéutica en fase comercial, anunció su participación en dos conferencias para inversores en septiembre de 2025: el Cantor Global Healthcare Conference el 3 de septiembre a las 9:45 a.m. ET y el H.C. Wainwright 27th Annual Global Investment Conference el 8 de septiembre a las 2:00 p.m. ET.
La empresa se especializa en medicamentos orales aprobados por la FDA, de toma diaria y no estatinos, para pacientes con LDL-C elevado y riesgo cardiovascular, avalados por el ensayo CLEAR de resultados cardiovasculares con 14.000 pacientes. Esperion también está desarrollando inhibidores de ATP citrato liasa (ACLYi) de nueva generación y ampliando su presencia global mediante alianzas y el avance de su cartera de productos.
Esperion (NASDAQ: ESPR)는 상업 단계의 생명공학 제약회사로, 2025년 9월 예정된 두 건의 투자자 콘퍼런스에 참가한다고 발표했습니다: 9월 3일 오전 9시 45분(동부시간) 개최되는 Cantor Global Healthcare Conference와 9월 8일 오후 2시(동부시간)의 H.C. Wainwright 27th Annual Global Investment Conference입니다.
이 회사는 FDA 승인된 경구용 비스타틴계(하루 한 번 복용) 약물을 전문으로 하며, LDL-C가 상승하고 심혈관계 위험이 있는 환자들을 대상으로 합니다. 이러한 약물들은 14,000명의 환자를 대상으로 한 CLEAR 심혈관 결과 시험으로 뒷받침됩니다. Esperion은 차세대 ATP 시트르산 분해효소(ACLY) 억제제도 개발 중이며, 파트너십과 파이프라인 개발을 통해 글로벌 확장을 추진하고 있습니다.
Esperion (NASDAQ: ESPR), une société biopharmaceutique en phase commerciale, a annoncé sa participation à deux conférences pour investisseurs en septembre 2025 : le Cantor Global Healthcare Conference le 3 septembre à 9h45 ET et le H.C. Wainwright 27th Annual Global Investment Conference le 8 septembre à 14h00 ET.
L'entreprise est spécialisée dans des médicaments oraux non-statine approuvés par la FDA, pris une fois par jour, destinés aux patients présentant un LDL‑C élevé et un risque cardiovasculaire, soutenus par l'essai CLEAR sur les résultats cardiovasculaires impliquant 14 000 patients. Esperion développe également des inhibiteurs de l'ATP citrate lyase (ACLYi) de nouvelle génération et étend sa présence mondiale via des partenariats et l'avancement de son portefeuille de développement.
Esperion (NASDAQ: ESPR), ein Biopharmaunternehmen in der kommerziellen Phase, gab seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 bekannt: der Cantor Global Healthcare Conference am 3. September um 9:45 Uhr ET und der H.C. Wainwright 27th Annual Global Investment Conference am 8. September um 14:00 Uhr ET.
Das Unternehmen spezialisiert sich auf von der FDA zugelassene orale, einmal täglich einzunehmende Nicht-Statin-Medikamente für Patientinnen und Patienten mit erhöhtem LDL‑C und kardiovaskulärem Risiko, gestützt durch die CLEAR-Studie zu kardiovaskulären Endpunkten mit 14.000 Teilnehmern. Esperion entwickelt außerdem Inhibitoren der ATP-Citrat-Lyase (ACLYi) der nächsten Generation und baut seine globale Präsenz durch Partnerschaften und die Weiterentwicklung der Pipeline aus.
- None.
- None.
ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of September, which can be found on our investor relations website.
Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET.
H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 p.m. ET.
Live webcasts can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion (ESPR) presenting at the Cantor Global Healthcare Conference 2025?
What time is Esperion's presentation at the H.C. Wainwright Conference in September 2025?
How can investors access Esperion's September 2025 conference presentations?
What are Esperion's main products and focus areas in 2025?
